Novartis and ProFound Therapeutics have announced a four-year collaboration to discover and develop novel therapeutics for cardiovascular disease. The collaboration will join ProFound’s capabilities in the identification of novel proteins from the expanded proteome as drugs and drug targets with Novartis’ cardiovascular drug development expertise. ProFound’s ProFoundry Platform combines multi-layered sources of biological data with […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!